Welcome to our dedicated page for Nordicus Partners SEC filings (Ticker: NORD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nordicus Partners Corporation filings document material-event disclosures for a public life sciences holding and business-acceleration company. The company’s Form 8-K reports cover capital-structure actions, including private placements and unregistered sales of restricted common stock under Securities Act exemptions.
The filing record also documents governance actions, including the establishment of board committees and adoption of Audit Committee, Compensation Committee, and Nominating Committee charters. These disclosures describe formal board structure, committee responsibilities, equity issuance terms, investor qualification representations, transfer restrictions, and related regulatory exemptions.
Nordicus Partners Corporation reported that from October through December 2025 it issued 416,000 restricted shares of its common stock in a private offering to eight investors at a price of $2.75 per share, and on December 5, 2025 determined to close the offering on these terms. The shares were sold without registration under the Securities Act of 1933, relying on exemptions including Section 4(a)(2), Rule 506(b) and (c) of Regulation D, and Regulation S. Investors were accredited and/or had access to information similar to a registration statement, acquired the stock for investment purposes, and the securities carry transfer restrictions and restrictive legends. No underwriters or agents participated, no underwriting discounts or commissions were paid, and there was no general solicitation.
Nordicus Partners Corporation (NORD) reported Q2 FY2026 results for the quarter ended September 30, 2025. The company recorded no revenue and a net loss of $1,511,474, or $0.08 per share. Operating expenses were $1,211,478, driven by officer compensation, R&D, and G&A. For the first six months, net loss totaled $2,718,360.
Liquidity remains tight. Cash was $242,155 as of September 30, 2025, after net cash used in operations of $2,188,401 in the six-month period. Financing cash inflows of $2,419,220 came from issuing 1,146,500 common shares. The company disclosed a going concern uncertainty due to nominal revenue, accumulated deficit of $49,503,208, and limited cash. Subsequent to quarter-end, it raised $618,750 via 225,000 restricted shares at $2.75 and repurchased 57,642 shares at $1.36.
Total assets were $75,882,821, including in-process R&D of $46,402,880 and goodwill of $27,696,030 tied to Orocidin A/S and Bio-Convert A/S. A fair-value decrease of $675,000 was recorded on the Mag Mile Capital investment over six months. Shares outstanding were 18,399,002 at quarter-end and 18,566,360 as of November 12, 2025.
Nordicus Partners (NORD) filed a Form 4 showing CEO Henrik Rouf sold company stock across four dates and updated his holdings. Reported sales were: 2,500 shares at $6 on 11/15/2024; 10,000 shares at $5 on 01/03/2025; 3,362 shares at $4.16 on 01/13/2025; and 26,667 shares at $2 on 08/20/2025.
Following these transactions, Mr. Rouf beneficially owns 15,973 shares. The filing notes a 1-for-10 reverse stock split effected on November 8, 2024. Of the 15,973 shares, 640 shares are held personally and 15,333 shares are held in the name of Reddington Partners LLC, for which Mr. Rouf is the sole beneficial owner.
Nordicus Partners Corp (NORD): Form 4 insider activity — A reporting person filed transactions spanning 12/19/2024 to 08/08/2025. Activity included conversions, open‑market buys and sells, and gifts. Notable entries: a conversion adding 10,000 shares at $10 on 12/19/2024; a purchase of 11,528 shares at $4 and sales of 54,223 and 7,500 shares at $4 and $3 on 02/03/2025; a conversion adding 11,224 shares at $8.91 on 02/13/2025; multiple purchases at $5 in May 2025; and a sale of 23,300 shares at $2 on 08/08/2025. Following the last reported transaction, beneficial ownership stood at 3,259,025 shares, held directly.
The filing notes gifts on 05/28/2025, including a gift from an affiliate shareholder, AC Nordic ApS, and private gift transfers.
Nordicus Partners Corp (NORD) Form 4: AC Nordic ApS, a reporting person and director, reported multiple purchases, sales and gifts of common stock between 02/18/2025 and 07/30/2025. The filing shows purchases: 2,000 shares at $5.00 (02/18/2025), 1,982 shares at $8.85 (06/02/2025), 35,000 shares at $4.00 (06/16/2025), 25,000 shares at $1.90 (07/02/2025), 42,500 shares at $1.90 (07/03/2025) and 100,000 shares at $1.90 (07/30/2025), plus a 109,750-share gift (05/28/2025) and a 113,095-share gift to GK Partners ApS (05/28/2025). Sales reported: 4,000 and 3,500 shares on 02/18/2025 at $1.90. Following the transactions the reporting person beneficially owned 3,119,335 shares. The form states transactions were reported late due to an inadvertent administrative error and is signed by the CEO.
AC Nordic ApS reports beneficial ownership of 3,119,335 shares of Nordicus Partners Corp common stock, representing 17.42% of 17,901,551 outstanding shares. The filing lists multiple private acquisitions between February and July 2025 at purchase prices ranging from $1.90 to $8.85 per share, purchases from the issuer on specific dates, and two gifts on May 28, 2025 totaling 222,845 shares (109,750 and 113,095). The reporting person, organized in Denmark and controlled by Torben Steen Jensen, states the transactions serve a long-term strategy of asset diversification and liquidity and disclaims any current plans to pursue corporate control, board changes, restructurings, or other material actions.
Nordicus Partners Corporation entered into a material definitive agreement involving a private sale of its common stock. From July through September 2025, the company issued a total of 1,057,500 restricted shares of common stock at a price of $1.90 per share to 54 private investors, and on September 18, 2025 it decided to close this private offering on those terms.
The shares were issued as unregistered securities under the Securities Act of 1933, relying on exemptions including Section 4(a)(2), Rule 506(b) and (c) of Regulation D, and Regulation S for non-U.S. persons. Investors were accredited and/or received information similar to a registration statement, purchased for investment purposes, and the offering involved no general solicitation, underwriters, or commissions. The securities carry transfer restrictions and are subject to restrictive legends reflecting their unregistered status.